News
NBY
--
0.00%
--
Biden to Order Mask Wearing on Federal Property
-Bloomberg
Bloomberg · 4d ago
MARA, GME, FRSX and ZOM among midday movers
Gainers: Live Ventures (LIVE) +87%.GameStop (GME) +63%.Exela Technologies (XELA) +51%.AMMO (POWW) +41%.Castor Maritime (CTRM) +35%.Acorda Therapeutics (ACOR) +32%.Root (ROOT) +32%.Ondas Holdings (ONDS) +30%.NuCana (NCNA) +26%.Foresight Autonomous (FRSX) +26%.Losers: Asia Pacific Wire & Cable (APWC) -27%.Zomedica (ZOM) -26%.Forward Pharma
Seekingalpha · 01/13 17:45
Acorda Therapeutics, NuCana leads healthcare gainers; Zomedica, Forward Pharma among major losers
Gainers: Acorda Therapeutics (ACOR) +45%, NuCana (NCNA) +26%, Synlogic (SYBX) +24%, Evoke Pharma (EVOK) +23%, Tiziana Life Sciences (TLSA) +14%.Losers: Zomedica (ZOM) -26%, Forward Pharma (FWP) -15%, Provention Bio (PRVB) -14%, Acutus Medical (AFIB) -13%, NovaBay Pharmaceuticals (NBY) -12%.
Seekingalpha · 01/13 16:01
Grubhub, Big Lots leads the premarket losers' pack
Marathon Patent Group (MARA) -19% after $250M capital raise.Zomedica (ZOM) -16%.Asia Pacific Wire & Cable Corporation (APWC) -16%.Harbor Custom Development (HCDI) -13% after pricing stock offering.Party City Holdco (PRTY) -12% after Q4 guidance falls short.Borr Drilling
Seekingalpha · 01/13 13:47
NovaBay Pharmaceuticals Now Included in EPA N Listing of Products That Kill SARS-CoV-2
NovaBay Pharmaceuticals announces its proprietary hypochlorous acid solution has received EPA approval for SARS-CoV-2 kill claim.
Business Wire · 12/14/2020 11:50
Innovations in Disinfection Technology Aid the Return of Workers
, /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. F...
PR Newswire - PRF · 12/09/2020 14:01
NovaBay Pharma rises 8% on Avenova distribution deal in Australia
NovaBay Pharmaceuticals (NBY) perks 8% premarket after signing an agreement with Paragon Care Group Australia Pty Ltd for the exclusive distribution of Avenova in Australia.Paragon Care Group will begin distributing Avenova directly to consumers under
Seekingalpha · 11/23/2020 12:37
NovaBay Pharmaceuticals Expands Avenova's Geographic Reach to Australia with New Exclusive Distribution Agreement
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market, announces the signing of an agreement with Paragon Care Group Australia Pty Ltd
Benzinga · 11/23/2020 11:53
NovaBay Pharmaceuticals Expands Avenovas Geographic Reach to Australia with New Exclusive Distribution Agreement
NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreement
Business Wire · 11/23/2020 11:50
NovaBay Pharmaceuticals Expands Avenova's Geographic Reach to Australia with New Exclusive Distribution Agreement
NovaBay(R) Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova(R) for the eye care market, announces the signing of an agreement with Paragon Care Group Australia Pty Ltd for the exclusive distribution o...
BusinessWire · 11/23/2020 08:50
NovaBay Pharmaceuticals Expands Avenova's Geographic Reach to Australia with New Exclusive Distribution Agreement
NovaBay(R) Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova(R) for the eye care market, announces the signing of an agreement with Paragon Care Group Australia Pty Ltd for the exclusive distribution of Avenova in Australia. Paragon Care Group will begin distributing Avenova directly to consumers under its Designs For Vision brand beginning in early 2021.
BusinessWire · 11/23/2020 08:50
President-Elect Biden Says Discussed Nationwide Mask Mandate With State Governors
-Reuters-Reuters
Reuters-Reuters · 11/19/2020 21:22
NovaBay Pharmaceuticals Q3 EPS $(0.08) Misses $(0.04) Estimate, Sales $2.17M Miss $2.52M Estimate
NovaBay Pharmaceuticals (AMEX:NBY) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.04) by 100 percent. This is a 300 percent decrease over losses of $(0.02) per share
Benzinga · 11/12/2020 21:23
NovaBay EPS misses by $0.04, misses on revenue
NovaBay (NBY): Q3 GAAP EPS of -$0.08 misses by $0.04.Revenue of $2.17M (+34.0% Y/Y) misses by $0.35M.Shares -1.4%.Press Release
Seekingalpha · 11/12/2020 21:10
NovaBay Pharmaceuticals Reports Third Quarter 2020 Financial Results
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2020 and provides a business update.
Business Wire · 11/12/2020 21:05
NovaBay Pharmaceuticals Reports Third Quarter 2020 Financial Results
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2020 and provides a business update.
Business Wire · 11/12/2020 21:05
NovaBay Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / NovaBay Pharmaceuticals, Inc. (NBY) (NYSE:NBY) will be discussing their earnings results in their call to be held on November 12, 2020 at 4:30 PM Eastern Time.
ACCESSWIRE · 11/12/2020 19:32
NovaBay Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / NovaBay Pharmaceuticals, Inc. (NBY) (NYSE:NBY) will be discussing their earnings results in their call to be held on November 12, 2020 at 4:30 PM Eastern Time.
ACCESSWIRE · 11/12/2020 19:32
NovaBay Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / NovaBay Pharmaceuticals, Inc.
ACCESSWIRE · 11/12/2020 19:30
NovaBay Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / NovaBay Pharmaceuticals, Inc.
ACCESSWIRE · 11/12/2020 19:30
Webull provides a variety of real-time NBY stock news. You can receive the latest news about NOVABAY PHARMA through multiple platforms. This information may help you make smarter investment decisions.
About NBY
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.
More